BioSpace News Archive

Public Listing offers Access to CAD 52 Million from Share Subscription and Drawdown Agreement, Sufficient Funding to Complete Development and Launch Avisa BreathTest™ Pivotal Trials Planned in Post-COVID-19 Long Haulers and Ventilator-Associated Pneumonia

Bristol Myers Squibb (NYSE: BMY) today announced that the company will participate in a fireside chat at the UBS Global Healthcare Virtual Conference, which will be webcast on Tuesday, May 25, 2021. David Elkins, Executive Vice President, Chief Financial Officer and Samit Hirawat, M.D., Executive Vice President, Chief Medical Officer, Global Drug Development , will answer questions about the company at 1 p.m. ET.

CDR-Life Inc., a biotherapeutics company developing tumor-specific immunotherapies based on a proprietary antibody platform, announced the appointment of Dieter Gericke, a seasoned attorney and long-time corporate advisor to the life sciences industry, to its board of directors, effective May 17, 2021.

Brooklyn ImmunoTherapeutics , Inc. (NYSE American: BTX) (“Brooklyn” or the “Company”), a biopharmaceutical company currently focused on exploring the role that cytokine and gene editing/cell therapy can have in treating patients with cancer, blood disorders and monogenic diseases, today announced that management will host a conference call on Tuesday, May 25, 2021 at 4:30 p.m. Eastern Time (ET).

Inovalon (Nasdaq: INOV), a leading provider of cloud-based platforms empowering data-driven healthcare, is hosting its Virtual Investor Day today at 10 a.m. ET. The Virtual Investor Day is expected to run approximately 2.5 hours.

Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a clinical stage biopharmaceutical company focused on developing targeted medicines for persons living with autoimmune disease, requiring an organ or cell-based transplant, or living with amyotrophic lateral sclerosis (ALS), today announced that management will present a corporate overview at the Jefferies Virtual Healthcare Conference on Tuesday, June 1, 2021 at 4:30pm EST .

Impel NeuroPharma (Nasdaq: IMPL), a late-stage biopharmaceutical company, today launched Reroute Migraine Relief , an educational initiative which aims to raise awareness of the complexities of migraine, including the underrecognized connection between the brain and gut.

CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, announced the grant of an inducement award to Dennis Kim, MD in connection with his appointment as the company’s Chief Medical Officer.

Dr. Connolly brings a commitment to diversity, equity, and inclusion as she leads the medical specialty society in 2021-22.

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that it has entered into a new development and commercialization license agreement with Santen Pharmaceutical Co., Ltd. (Santen) for the PRESERFLO™ MicroShunt